Effects of age on dopamine transporters in healthy humans

Journal of Nuclear Medicine

Volumn 40, Issue 11, 1999, Pages 1812-1817

  Mozley, P David ^a,b   Acton, Paul D ^a   Barraclough, Eleathea D ^a   Plössl, Karl ^a   Gur, Ruben C ^a   Alavi, Abass ^a   Mathur, Ajit ^a   Saffer, Janet ^a   Kung, Hank F ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

99mTc; Normal; Tomography emission computed

Indexed keywords

DOPAMINE TRANSPORTER; TECHNETIUM 99M;

ADULT; AGED; AGING; ARTICLE; BASAL GANGLION; BRAIN SCINTISCANNING; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY;

ADULT; AGING; ALGORITHMS; BRAIN; CARRIER PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0032719121     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharmac Sci. 1993;14:43-49.
2. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and methamphetamine in mice lacking the dopamine transporter. Nature. 1996;379:606-612.
3. Johanson CE, Fischman M. The pharmacology of cocaine related to its abuse. Pharmacol Rev. 1989;41:3-52.
4. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in healthy human subjects. Ann Neurol. 1994;36:237-239.
5. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med. 1995;36:1175-1181.
6. Volkow ND, Ding Y-S, Fowler JS, et al. Dopamine transporters decrease with age. J Nucl Med. 1996;37:554-559.
7. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996;37:1760-1765.
8. Mozley PD, Kim H-J, Gur RC, et al. [I-123]IPT SPECT imaging of CNS dopamine transporters: non-linear effects of normal aging on striatal uptake values. J Nucl Med. 1996;37:1965-1970.
9. Frost JJ, Rosier AJ, Reich SG, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked decline in mild Parkinson's disease. Ann Neurol. 1993;34:423-431.
10. Innis RB, Seibyl JP, Scanley BE, et al. Single-photon emission-computed tomography imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA. 1993;90:11965-11969.
11. Tatsch K, Schwarz J, Mozley PD, et al. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [I-123] IPT single-photon emission tomography. Eur J Nucl Med. 1997;34:415-421.
12. Meegalla S, Plössl K, Kung MP, et al. Tc-99m-labeled tropanes as dopamine transporter imaging agents. Bioconjugate Chem. 1996;7:421-429.
13. Kung HF, Kim HJ, Rung MP, Meegalla SK, Plössl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med. 1996;23:1527-1530.
14. Meegalla SK, Plössl K, Kung MP, et al. Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents. J Med Chem. 1997;40:9-17.
15. 99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med. 1997;24:372-380.
16. 99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med. 1998;25:31-39.
17. 99mTc]TRODAT-1 as dopamine transporter imaging agents. J Med Chem.1998;41: 428-436.
18. Mozley PD, Stubbs JB, Plössl K, et al. Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters. J Nucl Med. 1998;39:2069-2076.
19. Kim H-J, Karp JS, Mozley PD, et al. Simulating technetium-99m cerebral perfusion studies with a three-dimensional Hoffman brain phantom: collimator and filter selection in SPECT neuroimaging. Ann Nucl Med. 1996;10:153-160.
20. 99mTc]TRODAT-1: a novel compound for imaging the dopamine transporter. J Nucl Med. 1999;40:150-158.
21. Acton PD, Friston KF. Statistical parametric mapping in functional neuroimaging: beyond PET and fMRI activation studies. Eur J Nucl Med. 1998;25:663-667.
22. Hoh CK, Dahlbom M, Harris G, et al. Automated iterative three-dimensional registration of positron emission tomography images. J Nucl Med. 1993;34:2009-2018.
23. Friston KJ, Frith CD, Liddle PF, Dolan RJ, Lammertsma AA, Frackowiak RSJ. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab. 1990;10:458-466.
24. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric mapping in functional imaging: a general linear approach. Hum Brain Mapping. 1995;2:189-210.
25. Worsley KJ. Local maxima and the expected Euler charactersitic of excursion sets of chi-2, F and t fields. Adv Appl Prob. 1994;26:13-42.
26. Martin WRW, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in man studied with positron emission tomography. Ann Neurol. 1989;26:535-542.
27. Cordes M, Snow BJ, Cooper S, et al. Age-dependent decline of nigrostriatal dopaminergic function: a positron emission tomographic study of grandparents and their grandchildren. Ann Neural. 1994;36:667-670.
28. Vingerhoets FJG, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994;36:759-764.
29. 11C]-raclopride. Ann N Y Acad Sci. 1993;695:81-85.
30. 11C-raclopride. Neurology. 1993;50:474-480.
31. Wong DF, Young D, Wilson PD, Meltzer CC, Gjedde A. Quantification of neuroreceptors in the living human brain: III. D2-like dopamine receptors: theory, validation, and changes during normal aging. J Cereb Blood Flow Metab. 1997;17:316-330.
32. 2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med. 1998;39:1511-1518.
33. Sawle GV, Colebatch JG, Shah A, et al. Striatal function normal aging: implications for Parkinson' disease. Ann Neurol. 1990;28:799-894.
34. Mozley PD, Sadek AH, Alavi A, et al. Effects of aging on the cerebral distribution of [Tc-99m] HMPAO in healthy humans. Eur J Nucl Med. 1997;24:754-761.
35. Lezak MD. Neuropsychological Assessment. 2nd ed. New York, NY: Oxford University Press; 1983.
36. Bak JS, Greene RL. Changes in neuropsychological functioning in an aging population. J Consult Clin Psychol. 1980;48:395-399.
37. Harley JP, Leuthold CA, Matthews CG, Bergs LE. Wisconsin Neuropsychological Test Battery t-Score Norms for Older Veterans Administration Medical Center Patients. Madison, WI: CG Matthews; 1980.
38. Heaton RK, Grant I, Matthews CG. Differences in neuropsychological test performance associated with age, education, and sex. In: Grant I, Adams KM, eds. Neuropsychological Assessment of Neuropsychiatric Disorders. New York, NY: Oxford University Press; 1986:100-120.
39. Heaton RK, Grant I, Matthews CG. Comprehensive Norms for an Expanded Halstead-Reitan Battery. Odessa, FL: Psychological Assessment Resources; 1991:5-13.
40. Morris ED, Chefer SI, Lane MA, et al. Loss of D2 receptor binding with age in rhesus monkeys: importance of correction for differences in striatal size. J Cereb Blood Flow Metab. 1999;19:218-229.